SCM just pulled one of his stupidest calls ever.  He

New Post Public Reply Private Reply Replies (2) Message Board
HerbertJStockman
SCM just pulled one of his stupidest calls ever.  He actually called Gold an idiot because they don't have clinical trials in place for Dharmanol like are going on for Sativex.  Would someone who goes on that board please point out to him that it is difficult to have clinical trials for a new medicine in place ONE DAY after it is announced.

Sativex has been legal in different countries for years, and it is just now getting clinical trials in the U.S. The trials are for controlling cancer pain, not treating the disease itself. Sativex has gone through the regulatory processes in many countries, and is two or three years behind the times, considering the progress that science has made in figuring out that mmj might actually cure the  cancer itself in big enough doses. The reason that B-bio is so far ahead of Sativex (a simple 1 to 1 mixture of THC and CBD) is that they are working as scientists should, going at it full speed ahead under state laws which permit them to go for it in spite of the federal red tape that keeps researchers who rely on govt. funding from making much progress at all in this area.

SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Zhihu Inc. Announces Annual Report Submission for 2024

Updated Category News Views 157

Zhihu Inc. Submits Annual Report for 2024 BEIJING — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a front-runner in China's online content community ecosystem, is pleased to announce the submission of its annual report on Form 20-F for the fiscal year observed until December 31, 2024. This report was officially filed with the Securities and...

Continue Reading
Debbie Wasserman Schultz's Strategic Trades in Key Companies

Updated Category News Views 1462

Congresswoman Debbie Wasserman Schultz's Recent Stock Transactions In the latest congressional trading report, Congresswoman Debbie Wasserman Schultz, a prominent figure, has made noteworthy moves in the stock market. Her recent trades reveal a strategic approach to investing in various sectors, particularly the healthcare and mining industries. Investments in Baxter...

Continue Reading
LifeMD, Inc. Securities Class Action: How to Join the Fight

Updated Category News Views 166

LifeMD, Inc. Securities Class Action Overview The Rosen Law Firm, renowned for its expertise in investor rights, is encouraging investors of LifeMD, Inc. to act quickly in a significant securities class action. This class action is a result of allegations of misleading statements made by the company, and the clock is ticking toward important legal deadlines. Why Act Now?...

Continue Reading
SPX FLOW's Innovation Shines Again with Sustainable Award

Updated Category News Views 93

SPX FLOW Achieves Recognition for Sustainable Innovation SPX FLOW, a renowned leader in process solutions, has once again showcased its commitment to sustainability by winning a prestigious SEAL Business Sustainability Award. This honor, received for the second consecutive year, highlights the company’s innovative approach through the launch of the Seamless Infusion...

Continue Reading
Exploring Bonduelle's Monthly Share and Voting Rights Status

Updated Category News Views 131

Understanding Bonduelle’s Monthly Share and Voting Rights Update Bonduelle, a prominent name in the agri-food sector, is renowned for its commitment to quality and sustainable practices. This article provides a detailed overview of the company's monthly insights regarding shares and voting rights. Such transparency is crucial for investors and stakeholders who follow...

Continue Reading